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Abstract 20 
A high performance liquid chromatography - tandem mass spectrometry (LC-MS/MS) 21 
method, using hydrophilic interaction liquid chromatography (HILIC) 22 
chromatography for the analysis of fosfomycin in human plasma and urine, has been 23 
developed and validated. The plasma method uses a simple protein precipitation 24 
using a low volume sample (10 μL) and is suitable for the concentration range of 1 to 25 
2000 μg/mL. The urine method involves a simple dilution of 10 μL of sample and is 26 
suitable for a concentration range of 0.1 to 10 mg/mL. The plasma and urine results, 27 
reported respectively, are for recovery (68, 72%), inter-assay precision (≤9.1%, 28 
≤8.1%) and accuracy (range -7.2 to 3.3%, -1.9 to 1.6%), LLOQ precision (4.7%, 3.1%) 29 
and accuracy (1.7% and 1.2%), and includes investigations into the linearity, stability 30 
and matrix effects.  The method was used in a pilot pharmacokinetic study of a 31 
critically ill patient receiving IV fosfomycin, which measured a maximum and 32 
minimum plasma concentration of 222 μg/mL and 172 μg/mL, respectively, after the 33 
initial dose, and a maximum and minimum plasma concentration of 868 μg/mL and 34 
591 μg/mL, respectively, after the fifth dose. The urine concentration was 2.03 35 
mg/mL after the initial dose and 0.29 mg/mL after the fifth dose. 36 
 37 
HIGHLIGHTS 38 
 A simple and robust LC-MS/MS method for the quantification of fosfomycin 39 
in human plasma and urine has been developed. 40 
 The method uses HILIC chromatography that supports a simple treatment of 41 
fosfomycin from biological fluids. 42 
 The developed LC–MS/MS method has been validated according to published 43 
US FDA guidelines and shows excellent performance. 44 
 Results of a critically ill patient from a pilot pharmacokinetic study with 45 
receiving IV fosfomycin are included. 46 
 This is the first method published that is suitable for the quantification of 47 
fosfomycin in both plasma and urine. 48 
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 50 
1. Introduction 51 
Fosfomycin (FOM) is a broad-spectrum antibiotic that is generating substantial 52 
interest as an intravenous or enteral therapy for the treatment of multi-drug 53 
resistant (MDR) infections [1, 2]. Antibiotic resistance is a significant and immediate 54 
global health concern and an increasing prevalence of MDR bacteria is steadily 55 
decreasing the number of usable antibiotics available [3]. In this context, fosfomycin 56 
represents an important treatment option. 57 
FOM was first discovered in Spain in 1969 and is used as treatment therapy for 58 
uncomplicated urinary tract infections [4] and often combined with beta-lactams or 59 
aminoglycosides for a synergistic effect against Pseudomonas aeruginosa [5, 6]. FOM 60 
is structurally unrelated to other antibiotics: it is a small (138 Da), highly hydrophilic 61 
phosphonic acid and, with negligible protein binding [7], exhibits excellent 62 
penetration into tissue [8]. FOM has a unique mechanism of action by way of its 63 
ability to inhibit the synthesis of peptidoglycan found in the inner cell wall of Gram-64 
negative and Gram-positive bacteria [9]. These characteristics support the 65 
effectiveness of FOM for the treatment of MDR pathogens and it has been used 66 
extensively as a last-line antibiotic for treatment of critically ill patients [2]. 67 
Investigating the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of 68 
FOM may enable development of robust dosing strategies that maximize the PD 69 
response to treatment while minimizing the potential future development of 70 
antibiotic resistance. A reliable method of quantification of FOM in plasma is needed 71 
to define the pharmacokinetic profile of the drug and urine data can provide 72 
valuable information on elimination rates. The information obtained can be used to 73 
characterize the PK/PD relationship. 74 
There are several analytical techniques available for the determination of FOM in 75 
biological fluids, using gas chromatography [10-14], liquid chromatography (LC) - 76 
spectrophotometric detection [15], LC - photometric detection [16], capillary zone 77 
electrophoresis [17, 18], and, more recently, with derivatization and LC - 78 
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atmospheric pressure chemical ionization mass spectrometry [19] and LC – tandem 79 
mass spectrometry (MS/MS) [20-22]. 80 
A method suitable for use in a pharmacokinetic study with patients receiving 81 
multiple intravenous doses, up to around 12-24 g/day (as are now being used 82 
clinically [2]) would require a lower limit of quantification (LLOQ) of around 1 μg/mL 83 
for plasma and 0.1 mg/mL for urine. However, patients with renal insufficiency or 84 
with altered pharmacokinetics – as is commonly seen in the critically ill – receiving 85 
multiple doses of antibiotics can exhibit very high concentrations in their plasma. 86 
This has, therefore, led to an unusually extended concentration range (from 1 to 87 
2000 μg/mL for plasma) being described here, which is supported by the data from 88 
the pilot study. While there are many methods currently available for the analysis of 89 
FOM in biological fluids, and the method by Li offers a rapid and sensitive alternative 90 
for plasma [20], we are unaware of any methods suitable for the analysis of FOM in 91 
both plasma and urine that offer the concentration range to meet these clinical 92 
specifications at this time. 93 
This paper describes an analytical technique using hydrophilic interaction 94 
chromatography (HILIC) – tandem mass spectrometry that offers a simple and 95 
reliable determination of FOM in plasma and urine, with a quick and reproducible 96 
sample preparation.  97 
2. Experimental  98 
2.1. Chemicals and materials 99 
Fosfomycin (FOM), ethylphosphonic acid (EPA, internal standard) and acetonitrile 100 
(HPLC gradient-grade solvent) were purchased from Sigma-Aldrich and ammonium 101 
acetate was obtained from Ajax Univar. Ultra-pure water was obtained using a 102 
Permutit system. Drug-free human plasma was obtained from the Australian Red 103 
Cross Blood Service and drug-free urine was obtained from healthy volunteers. 104 
2.2. Instrumentation and conditions 105 
The LC-MS/MS used is a Shimadzu Nexera UHPLC equipped with a triple quadrupole 106 
8030+ Shimadzu mass spectrometer (MS) detector. An electro-spray ionization (ESI) 107 
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source interface operating in negative-ion mode was used for the multiple reaction 108 
monitoring (MRM) LC-MS/MS analysis. MS conditions for FOM and the internal 109 
standard (IS; EPA) are reported in Table 1. The interface settings consisted of the 110 
nebulizing gas flow of 3 L/min, a de-solvation line temperature of 250°C, heat block 111 
temperature of 400°C and a drying gas flow of 15 L/min.   112 
The compounds were separated on a Merck SeQuant zic-HILIC, 2.1 x 50 mm, 5.0 μm 113 
analytical column (operated at 24° C) protected by a 20 mm SeQuant zic-HILIC 114 
guard cartridge using an isocratic mobile phase containing acetonitrile with 2 mM 115 
ammonium acetate, pH 4.8 (85/15 v/v) at a flow rate of 0.3 mL/min. The injection 116 
volumes used were 0.1 μL for the plasma assay and 0.5 μL for the urine assay. The 117 
retention time for both FOM and EPA was 2.5 min. 118 
2.3. Stock and standard solution preparation 119 
2.3.1. Standards for plasma analysis 120 
Aqueous stock solutions for plasma standard preparation (at 1, 2 and 10 mg/mL) 121 
were stored at -80°C. On the day of assay these were diluted with drug free plasma 122 
to yield calibration standards from 1 to 2000 µg/mL that was processed alongside 123 
the clinical samples. 124 
2.3.2. Standards for urine analysis 125 
Aqueous stock solutions for urine standards of FOM (2, 5, 10, and 50 mg/mL) were 126 
stored at -20°C. On the day of assay these were diluted with drug free urine to 127 
prepare calibration standards from 0.1 to 10 mg/mL that were processed alongside 128 
the clinical samples. 129 
2.3.3. Internal standard solution  130 
Ethylphosphonic acid (EPA) in acetonitrile was used as internal standard for the 131 
plasma assay (10 µg/mL), and an aqueous EPA solution was used as internal standard 132 
for the urine assay (1 mg/mL).  Solutions were stored at -20°C.  133 
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2.3.4. Quality Controls 134 
Quality controls were prepared by spiking drug free plasma with FOM to 135 
concentrations of 3, 800 and 1600 µg/mL, and stored at -80°C until assay. On the day 136 
of assay an additional QC at 80 µg/mL was prepared by diluting with blank plasma 137 
the QC at 800 µg/mL. The four sets of QCs were assayed alongside clinical samples. 138 
Quality controls for urine analysis were prepared at FOM concentrations of 0.3, 2 139 
and 8 mg/mL.  The urine QCS were stored at -20°C until assayed alongside clinical 140 
samples. 141 
2.4. Analytical procedure 142 
2.4.1. Clinical plasma sample preparation 143 
Clinical samples were prepared by combining 10 μL of clinical sample, 10 μL of 144 
water, and 90 μL of drug-free blank plasma. Internal standard (300 μL, 10 μg/mL of 145 
EPA in acetonitrile) was then added and the sample vortexed and then centrifuged 146 
(for 5 min at 14,000 rpm) to remove precipitated proteins. A volume of 0.1 μL was 147 
injected onto the LC-MS/MS system. 148 
2.4.2. Clinical urine sample preparation 149 
All urine samples were filtered using a 0.22 µm filter prior to use. Clinical samples 150 
were prepared by combining 10 μL of sample with 10 μL water, followed by internal 151 
standard (20 μL, 1 mg/mL of EPA). The sample was then diluted with 200 μL of 152 
mobile phase and 0.5 μL was injected into the LC-MS/MS system. 153 
2.4.3. Data analysis 154 
For both plasma and urine the concentration of each clinical sample was obtained 155 
using the data from the calibration curve prepared (in either plasma or urine) within 156 
the batch using a quadratic regression with peak-area ratio (drug/internal standard 157 
area responses) against concentration (x), with a 1/x2 weighting as the mathematical 158 
basis of the quantification.  159 
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2.5. Validation 160 
The validation was performed in accordance with the guidelines provided by the US 161 
Food and Drug Administration (USFDA) and met the criteria required to demonstrate 162 
the method is suitable for intended purpose [23]. The validation for both plasma and 163 
urine was assessed for matrix effects, lower limit of quantification (LLOQ), linearity, 164 
inter-day precision and accuracy, freeze-thaw stability of quality control samples and 165 
the stability of standard solutions.  166 
2.5.1. Limit of quantification 167 
The lower limits of quantification for FOM were evaluated by analysis of replicate 168 
standards, for both plasma and for urine samples.  169 
2.5.2. Linearity 170 
To investigate linearity, calibration curves were prepared using the corresponding 171 
concentration ranges suitable for each matrix.  172 
2.5.3. Inter-day precision and accuracy 173 
Precision and accuracy for FOM throughout the calibration range of both plasma and 174 
urine was evaluated by the analysis of QC samples at four different concentrations 175 
for plasma and three different concentrations for urine with the QC concentrations 176 
determined against freshly prepared standard curves. In addition to precision and 177 
accuracy data obtained from QC samples, an incurred sample reanalysis was 178 
performed. 179 
Acceptance criteria were applied according to the US Food and Drug Administration 180 
guidelines [23]; with acceptance criteria on an incurred sample reanalysis applied 181 
according to the European Medicines Agency guidelines [24]. 182 
2.5.4. Matrix effects 183 
Plasma matrix effects were evaluated to identify any suppression or enhancement of 184 
signal from an interfering substance around the retention time of FOM and EPA by 185 
using the matrix factor test. Five blank plasma samples were assayed at spiked low 186 
and high concentration levels and with internal standard, and the area results 187 
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compared to those produced following the same extraction procedure using water 188 
instead of plasma. The precision of the matrix factor (normalized against the internal 189 
standard) was used to determine if any concentration level demonstrated a trend of 190 
variation from the expected result.  191 
Five urine blanks were assayed at a spiked low and high concentration level and the 192 
precision and accuracy calculated, with respect to the nominal concentrations, to 193 
determine if any concentration level demonstrated a trend of variation from the 194 
expected result. 195 
2.5.5. Recovery 196 
The recovery of FOM and EPA was evaluated by comparing the peak area for plasma 197 
or urine samples spiked prior to protein precipitation (for plasma) or dilution (for 198 
urine) with samples spiked after protein precipitation or dilution. Care was taken to 199 
ensure the injection matrix was identical in comparable samples. 200 
2.5.6. Stability 201 
Stability of FOM in plasma and urine was assessed across three freeze-thaw cycles 202 
(from -80°C to ambient temperature) using three replicates of the QC samples at 203 
low, medium and high concentrations. Stability of stock solutions was assessed 204 
comparing aqueous solutions stored at both -20°C and -80°C to freshly prepared 205 
solutions. 206 
2.6. Pharmacokinetic application 207 
The method was developed for the analysis of plasma and urine samples from a 208 
pharmacokinetic study with critically ill patients receiving an intravenous dose of 6 g 209 
of FOM every 6 hours with expected peak plasma concentrations of around 200 210 
µg/mL, an expected plasma half-life of 2 h, and urinary concentrations of around 5 211 
mg/mL [25].  212 
One critically ill patient was administered an intravenous dose of 6 g fosfomycin 213 
disodium. Blood samples (3 mL) were taken prior to dosing (0 h) and 0.5, 0.75, 1, 1.5, 214 
2, 4, and 6 h post administration using heparinized vacuum tubes (Greiner Bio-One, 215 
Vacuette® LiHep) on the first day of FOM administration and after receiving the fifth 216 
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FOM dose. Blood samples were centrifuged at 3000 rpm for 10 min to obtain plasma 217 
samples. Plasma samples were transferred into 2 mL polypropylene tubes, capped 218 
and stored at -80°C until analysis.  219 
Similarly, a urine sample was collected 6 h post administration of the FOM dose. The 220 
urine was transferred into a urine specimen vial, capped and stored at -80°C until 221 
analysis.  222 
This procedure was conducted in accordance with the principles laid down by the 223 
ICH guidelines for Good Clinical Practice and approved by the University of 224 
Queensland Medical Research Review Committee (clearance # 2012000870) and the 225 
Epistimoniko Symvouleio (Scientific Committee) of Attikon University Hospital 226 
(approval MEΘ-84/13-3-12). 227 
3. Results and discussion 228 
3.1. Chromatography 229 
This method has been established using HILIC technology which offers excellent 230 
selectivity for polar hydrophilic compounds like FOM, and the use of a high organic-231 
solvent content in the mobile phase leads to a rapid evaporation of the solvent 232 
during electrospray ionization [26], endowing the method with a simple 233 
compatibility with mass spectrometry. Additionally, the use of HILIC technology in 234 
this method obviates the requirement for further modification of the sample, after a 235 
solvent-based protein precipitation, to closely correspond with the organic content 236 
of the mobile phase for improved peak shape. This simplicity of extraction leads to 237 
low detection levels when using low sample volumes. 238 
Retention of the analyte by the stationary phase is caused by hydrophilic partitioning 239 
within an aqueous-enriched liquid layer and/or with the positive or negative charges 240 
on the HILIC stationary phase [27]; the balance of the partition is provided by the 241 
aqueous content and pH of the mobile phase. Therefore, the aqueous layer is critical 242 
to the efficiency of HILIC separation. Published HILIC methodology often 243 
recommends mobile phases consisting of high ionic strength (from 5 – 20 mM, with 244 
upper limits of 200-300 mM) [28] but this presented difficulties in development. The 245 
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use of mobile phases with high ionic strength of buffers, low and variable aqueous 246 
content, combined with the high pressure applied in an HPLC system led to blocking 247 
of the column and the capillary in the ionization source on the mass spectrometer. 248 
This isocratic method uses a low ionic strength of 2 mM ammonium acetate buffer in 249 
85% acetonitrile which has been reliable and provided consistent results with 250 
minimal loss to chromatographic shape and reproducibility. Regenerating the 251 
column after every 300 – 400 injections of samples, particularly the urine samples, 252 
and keeping buffer concentration to as low an ionic strength as possible, was 253 
advantageous to long term use. Using a guard column extended the column life but 254 
as the separation is highly dependent on the salt concentration and its impact on the 255 
stationary phases aqueous-rich layer, the regeneration of the column was critical to 256 
maintaining the quality of chromatography. 257 
Another aspect of the method development that was found to affect both the 258 
chromatographic retention and peak shape was the injection volume and the 259 
composition of the sample being injected. Despite the low injection volumes being 260 
used, 0.1 μL for plasma and 0.5 μL for urine, we conclude that the changes in the 261 
quality of the chromatography observed were due to the sensitivity of the 262 
interaction of FOM with the stationary phase from changes in ionic strength and pH 263 
of the buffer [26, 27]. For the development of a bio-analytical assay using HILIC 264 
chromatography, consideration of the organic to aqueous ratio, concentration of 265 
salts, and finally, the presence of acids or base, is required. A dilution with plasma 266 
was used in the plasma method as the ratio of acetonitrile to aqueous concentration 267 
had an impact on the quality of the chromatographic peak shape and retention; the 268 
concentrations found in clinical samples from the pilot study allowed this dilution.  269 
The urine method included a dilution of sample that improved the chromatographic 270 
separation by either reducing the presence of endogenous salts in the sample or 271 
controlling the pH.  272 
Buszewski [26] and Alpert describe the mechanism of HILIC separation as being 273 
based on an interplay of a partitioning equilibrium in the aqueous layer (based on 274 
the hydrophilicity of the analyte), weak electrostatic mechanisms, and dipole-dipole 275 
interactions (including hydrogen-bonding) [29] the impact of each parameter on the 276 
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selectivity and reproducibility of chromatography requires a more sophisticated 277 
management than in general reversed-phase chromatography, but which once 278 
overcome can lead to a highly stable and robust method. 279 
3.2. Validation 280 
The LLOQ was determined as 1 μg/mL for plasma and 0.1 mg/mL urine with 281 
precision calculated as 4.7 and 3.1%, respectively, and accuracy calculated as 1.7 and 282 
1.2%, respectively (Table 2). The signal to noise ratio of the lowest standard in the 283 
calibration curve was 23.2 for plasma and 178 for urine and this data, combined with 284 
the excellent precision and accuracy obtained at 1 μg/mL for plasma and 0.1 mg/mL 285 
for urine, suggests substantial scope for achieving a lower LLOQ for both matrices 286 
(see Figure 2 and 3 for a representative chromatogram of the LLOQ standard 287 
extracted from plasma and urine, respectively). The lower limit of detection (LLOD) is 288 
defined as being reliably distinguished from the background noise and calculated as 289 
≥ three-times the noise of the blank plasma sample. From the validation the LLOD 290 
was determined as being approximately 0.01 μg/mL for plasma and <0.01 mg/mL for 291 
urine.  292 
A regression model with a weighted (1/x2) quadratic curve provided the lowest 293 
distribution of error across the substantial concentration range (1 to 2000 μg/mL for 294 
plasma and 0.1 to 10 mg/mL for urine). The results of the linearity study are 295 
described in Table 3.  296 
Precision and accuracy of the QC samples are shown in Table 4 for both plasma and 297 
urine. All results were within the acceptance criteria of ± 15% of the nominal 298 
concentration, indeed the results of all plasma QCs samples were within 9.1% and 299 
urine within 4.2%. An incurred sample reanalysis was performed on a subset of 300 
clinical samples and the results meet the current guidelines [23, 24] with >67% of 301 
repeated results being within 30% of the mean. Indeed, 100% of the repeated results 302 
were within 11%. 303 
No signal suppression/enhancement was evident for either FOM or the internal 304 
standard from the matrix study performed. The matrix effect evaluation is reported 305 
in Table 5. 306 
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Despite using a very simple protein-precipitation for the extraction of FOM from 307 
plasma the recovery was somewhat low at 68%. However, this extraction recovery is 308 
not atypical for a drug with a highly hydrophilic nature due to preferential aqueous 309 
partitioning. As was seen from the LLOQ testing, the variability was reliable 310 
(precision 6.1%) and sensitivity (LLOD ca. 0.01 μg/mL) easily achievable. The recovery 311 
of the internal standard EPA was good at 72% when tested at the undiluted 312 
concentration of 10 μg/mL. The urine preparation was a simple dilution with internal 313 
standard and as such provided recoveries of 98% when tested at 0.4 mg/mL. The 314 
recovery results are reported in Table 5. 315 
Stock solution stability for FOM was tested for aqueous solutions stored for over 16 316 
months at -80°C and for over 11 months at -20°C and it was found to be stable. FOM 317 
was also found to be stable in plasma and urine across three freeze-thaw cycles 318 
when stored at -80°C and thawed at ambient temperature in water (see Table 5). 319 
Overall, the validation of this method was highly successful for both plasma and 320 
urine with the method showing an excellent degree of reproducibility and accuracy, 321 
and is suitable for use in the analysis of patient samples in a pharmacokinetic study. 322 
This technique offers a simple and robust method for the analysis of FOM in both 323 
plasma and urine in patient samples. Other quantitative methods have been 324 
described for the determination of FOM in serum or plasma [10, 12, 14, 15, 20, 22] 325 
and urine [11]. However, these methods often require a significant amount of time 326 
in sample preparation or technique, and none offer a chromatographic system 327 
suitable for a pharmacokinetic study of FOM in both plasma and urine. 328 
3.3. Pharmacokinetic analysis 329 
The plasma concentration-time profile obtained in the pilot pharmacokinetic study is 330 
shown in Figure 4. The peak plasma concentration in this patient after receiving the 331 
initial dose was 222 µg/mL, and the trough concentration was 141 µg/mL. Increased 332 
plasma concentrations were observed after receiving the fifth dose of FOM, with the 333 
peak plasma concentration recorded as 868 µg/mL, and the trough concentration 334 
was 592 µg/mL. The urinary concentration determined from a 6 h sample taken 335 
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post-dose and was 2.03 mg/mL after the initial dose and 0.29 mg/mL after the fifth 336 
dose of FOM.  337 
4. Conclusion 338 
The developed analytical method is a sensitive, simple and robust tool to analyse 339 
FOM in plasma and urine of patients. With the increasing prevalence of MDR 340 
organisms and the reduced effectiveness of currently available antibiotics this 341 
method allows the opportunity to study the disposition of FOM, particularly in at-risk 342 
patient groups. This research may improve dosing strategies which could minimize 343 
the risk of increasing resistance and bring an effective antibiotic back into the hands 344 
of treating physicians.  345 
346 
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 347 
Table 1. MS conditions for FOM and EPA 348 
MS FOM EPA 
Product Ion 137.1 (M.H-) 109.1 (M.H-) 
Daughter Ion  78.9 78.9 
Dwell Time (ms) 100 100 
Q1 (V) +14 +10 
Q3 (V) +28 +13 
Collision Energy (V) +25 +20 
 349 
Table 2: Lower limit of quantification 350 
Matrix Mean  Precision (%) Accuracy (%) 
Plasma (n = 13) 1.02 µg/mL ±4.7 +1.7 
Urine (n = 7) 0.10 mg/mL ±3.1 +1.2 
 351 
Table 3: Linearity analysis  352 
Matrix Calibration Range  Correlation Coefficient 
(Mean) 
Maximum deviation* 
(%) 
Plasma (n=12) 1 to 2000 µg/mL 0.9963 -14.0 
Urine (n=5) 0.1 to 10 mg/mL 0.9959 +10.5 
* Reported maximum deviation from nominal (%) across all standard curves and all concentration levels. 353 
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 354 
Table 4: Inter-assay Precision and Accuracy 355 
Matrix Concentration Replicates Mean Accuracy (%) Precision (%) 
P
la
sm
a 
3 μg /mL  22 2.93 -2.4 9.1 
80 μg /mL 27 78.0 -3.1 7.8 
800 μg/mL 22 826 3.3 4.3 
1600 μg/mL 23 1486 -7.2 5.9 
U
ri
n
e
 0.3 mg /mL  9 0.30 0.0 4.2 
2 mg /mL 9 2.0 1.6 8.1 
8 mg/mL 9 7.9 -1.9 2.3 
 356 
 357 
Table 5: Matrix, recovery and freeze-thaw stability studies 358 
 359 
Study Matrix Concentration Mean Accuracy (%) Precision (%) 
M
at
ri
x 
Plasma 3 μg /mL  1.05
a
  8.8 
 800 μg /mL 0.98
a
  3.9 
Urine 0.2 mg/mL 0.189 4.6 7.2 
 5 mg/mL 5.36 -5.4 7.1 
R
ec
o
ve
ry
 
Plasma 80 μg /mL 68  7.7 
Urine 10 μg/mL 98  4.2 
St
ab
ili
ty
 (
fr
ee
ze
-t
h
aw
) 
Plasma 0.3 μg /mL  0.31 3.2 4.0 
 5 μg /mL 4.8 -3.1 5.4 
 80 μg /mL  86 7.2 5.8 
Urine 0.3 mg /mL 0.30 0.9 2.7 
  2.1 mg /mL 2.3 8.2 3.1 
 7.8 mg /mL 8.2 4.4 1.0 
a
 matrix factor: calculated as a ratio of peak area of FOM in the presence of matrix to the peak area in 360 
the absence of matrix (normalized using the internal standard). 361 
 362 
363 
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Figure	  1:	  Structure	  of	  fosfomycin	  (FOM,	  left)	  and	  the	  internal	  standard,	  
ethylphosphonic	  acid	  (EPA,	  right),[29,30].	  
	  
	  
	  
	  
	  
Figure 1
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Figure	  2:	  Chromatograms	  of	  a	  blank	  sample	  (top)	  and	  the	  LLOQ	  (1	  µg/mL)	  plasma	  
standard	  (FOM,	  centre;	  EPA,	  bottom).	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Figure	  3:	  Chromatograms	  of	  blank	  sample	  (top)	  and	  the	  LLOQ	  (0.1	  mg/mL)	  urine	  
standard	  (FOM,	  centre;	  EPA,	  bottom)	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Figure	  4:	  Plasma	  concentration	  –	  time	  profiles	  of	  FOM	  in	  a	  critically	  ill	  patient	  
receiving	  a	  6	  g	  FOM	  IV	  dose	  every	  6	  hours,	  for	  the	  first	  and	  fifth	  doses.	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